Biosimilar with Delivery Device

Chimera provided advice to an ex-US generic pharmaceutical manufacturer on 505(b)2 NDA strategy related to drug delivery device comparability for a biosimilar regulated as a drug. This included providing advice and interpretation of FDA inputs from a previous Type C meeting and reviews of publicly available information about the innovator/reference drug, in particular its delivery device.